AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|
20.7 C
New York
Tuesday, June 23, 2026

Tag: skin

newssourceFORcompanyinformationcontent1marketreleases

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

WALL STREET RAISES RECORD BREAKING $4.2 MILLION AT 15TH ANNUAL LEVERAGED FINANCE FIGHTS MELANOMA BENEFIT SUPPORTING THE MELANOMA RESEARCH ALLIANCE

NEW YORK, June 13, 2025 /PRNewswire/ -- More than 1,100 private equity leaders, financiers and attorneys packed the Museum of Modern Art on June...

Hydration Room Expands to Rancho Cucamonga with New Wellness Clinic Focused on Proactive, Personalized Care

RANCHO CUCAMONGA, Calif., June 13, 2025 /PRNewswire/ -- Hydration Room, a leader in medically guided IV therapy and proactive wellness treatments, proudly announces the opening...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

Leading Gut Health Company Seed Expands Retail Footprint with Nationwide Launch at Sprouts Farmers Market

Seed's clinically validated probiotic innovations are now available in all 450 Sprouts stores across the United States Following 500% revenue growth in the past...

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement...

Yoomi™ Babytech Launches Patented Technology to Revolutionize Baby Bottle-Feeding and Transform Breastfeeding Recovery

Featuring the world's fastest self-warming bottles and a breakthrough in skin revival science for nipple care for breastfeeding moms, Yoomi™sets a new standard, Saving...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSkin

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers